Go to content

Publications

467 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:

  1. Canagliflozin (Invokana) for the treatment of adults with 'type 2 diabetes mellitus'

    The WAR has approved a pharmacotherapeutic report for the medicine canagliflozin (Invokana) in film-coated tablets with 100 ...

    Report | 24-03-2014

  2. Delta-9-tetrahydrocannabinol and cannabidiol (Sativex) with patients with moderate to severe spasticity due to multiple sclerosis

    The WAR has approved a pharmacotherapeutic report for the medicine delta-9-tetrahydrocannabinol and cannabidiol (Sativex) spray ...

    Report | 24-02-2014

  3. Herpes zoster vaccine (Zostavax) for the prevention of herpes zoster and herpes zoster-related post-herpetic neuralgia

    The WAR reached the follow conclusions: Zostavax has an added therapeutic value in comparison with placebo for the prevention of ...

    Report | 24-02-2014

  4. Alhydran (BAP Medical BV) hydrating creams for burns, radiodermatitis and hand-foot syndrome

    Alhydran (or other hydrating (scar) creams) does not comply with established medical science and medical practice and is ...

    Report | 20-02-2014

  5. Deep Brain Stimulation in patients with therapy-resistant obsessive-compulsive disorder

    In the Netherlands this treatment is combined with cognitive behavioural therapy. This report is a summary of recommendations by ...

    Report | 09-12-2013

  6. Diabetes Package Scan

    In a package scan we analyse the adequacy and accessibility of the package of insured care for a particular disease. Does the ...

    Report | 02-12-2013

  7. Rivaroxaban (Xarelto) for the indication 'treatment of pulmonary embolism'

    The WAR has approved a pharmacotherapeutic report for the medicine rivaroxaban (Xarelto®) 15 mg tablet for oral use. In ...

    Report | 25-11-2013

  8. Catumaxomab (Removab) for the indication ‘malignant ascites’

    The most important effect of catumaxomab in clinical research is a statistically significant 35-day extension in ‘puncture-free ...

    Report | 29-10-2013

  9. Tapentadol (Palexia Retard) for the indication severe chronic pain

    The therapeutic value of tapentadol for the treatment of severe chronic pain in adults who can only be treated with opioid ...

    Report | 28-10-2013

  10. Mirabegron (Betmiga) for the indication overactive bladder syndrome

    The WAR approved the pharmacotherapeutic report of the medicine mirabegron (Betmiga). Its therapeutic value was determined via ...

    Report | 18-10-2013

Go to